All In Biotech

Drug Trial Radar · NCT05079425

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect After the Oral Administration of NXC736 in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 1, 2021

Primary completion

Nov 1, 2022

Study completion Nov 1, 2022

Sponsor

Lead sponsor
NEXTGEN BioscienceIndustry
Sponsor type
Industry
First posted
Oct 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo- controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male volunteers.

Conditions

  • Healthy

Interventions

  • NXC736Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Day 49
  2. Number of Participants with Serious Adverse Events (SAEs)Time frame: Day 49
  3. Number of Participants with Vital Sign AbnormalitiesTime frame: Day 49
  4. Number of Participants with Electrocardiogram (ECG) AbnormalitiesTime frame: Day 49
  5. Number of Participants with Clinical Laboratory AbnormalitiesTime frame: Day 49

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.